Transgene posts encouraging first-half results
This article was originally published in Scrip
Executive Summary
Transgene, the France-based biopharmaceutical company, has posted revenues of €5.5 million in the first half of this year. Excluding revenues from a €23 million partnership deal targeting the human papillomavirus signed with Rochelast year, the company's revenues more than tripled from €1.8 million last year.